Gaetano Macrì

Summary

Affiliation: University of Ferrara
Country: Italy

Publications

  1. pmc Abciximab: a reappraisal of its use in coronary care
    Marco Valgimigli
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago BS, Italy
    Biologics 2:29-39. 2008
  2. doi request reprint Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint ste
    Marco Valgimigli
    Interventional Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands Electronic address
    Am Heart J 166:831-8. 2013
  3. doi request reprint Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials
    Marco Valgimigli
    Cardiology Department, University of Ferrara, Italy Electronic address
    Int J Cardiol 168:2579-87. 2013
  4. doi request reprint Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Italy
    Int J Cardiol 165:134-41. 2013
  5. doi request reprint Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Ferrara, Italy
    Circulation 125:2015-26. 2012
  6. doi request reprint Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:268-77. 2012
  7. doi request reprint Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
  8. ncbi request reprint Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile
    Marco Valgimigli
    Section of Cardiology, University of Ferrara and Cardiovascular Research Centre, Arcispedale S Anna C rso Giovecca 203, 44100 Ferrara, Italy
    Eur Heart J 26:1838-45. 2005
  9. doi request reprint Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
    Marco Valgimigli
    Department of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
    J Cardiovasc Med (Hagerstown) 10:S17-26. 2009
  10. doi request reprint Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting
    M Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    J Thromb Haemost 8:1903-11. 2010

Detail Information

Publications29

  1. pmc Abciximab: a reappraisal of its use in coronary care
    Marco Valgimigli
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago BS, Italy
    Biologics 2:29-39. 2008
    ..Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future...
  2. doi request reprint Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint ste
    Marco Valgimigli
    Interventional Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands Electronic address
    Am Heart J 166:831-8. 2013
    ....
  3. doi request reprint Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials
    Marco Valgimigli
    Cardiology Department, University of Ferrara, Italy Electronic address
    Int J Cardiol 168:2579-87. 2013
    ..The potential benefits and risks of at least 1-year dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation remain uncertain...
  4. doi request reprint Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Italy
    Int J Cardiol 165:134-41. 2013
    ..5% in the BMS and 7.8% in the SES groups (P = 0.0039), reflecting a reduction of reintervention rates (10.2% vs. 3.2%). A three-year follow-up was performed to extend previous short- to mid-term findings...
  5. doi request reprint Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Ferrara, Italy
    Circulation 125:2015-26. 2012
    ..We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents...
  6. doi request reprint Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:268-77. 2012
    ....
  7. doi request reprint Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
    ..This study sought to assess whether transradial intervention, by minimizing access-site bleeding and vascular events, improves outcomes in patients with ST-segment elevation myocardial infarction compared with the transfemoral approach...
  8. ncbi request reprint Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile
    Marco Valgimigli
    Section of Cardiology, University of Ferrara and Cardiovascular Research Centre, Arcispedale S Anna C rso Giovecca 203, 44100 Ferrara, Italy
    Eur Heart J 26:1838-45. 2005
    ..We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI)...
  9. doi request reprint Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
    Marco Valgimigli
    Department of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
    J Cardiovasc Med (Hagerstown) 10:S17-26. 2009
    ..In conclusion, stent choice in primary PCI cannot be standardized for all patients and appears to be influenced by various factors that need to be considered to provide better revascularization in terms of both efficacy and safety...
  10. doi request reprint Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting
    M Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    J Thromb Haemost 8:1903-11. 2010
    ..The concomitant administration of high loading dose clopidogrel, by bridging with abciximab bolus, may sustain suppression of platelet activity over time...
  11. doi request reprint Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment
    Marco Valgimigli
    Cardiology Department, University of Ferrara, Ferrara, Italy
    Am Heart J 160:804-11. 2010
    ....
  12. doi request reprint Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy
    Marco Valgimigli
    University of Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago BS, Italy
    Am Heart J 160:S36-41. 2010
    ..Selection of agents and their combination, dose optimization, and a customized approach based on genotype or assessment of on-treatment phenotype are discussed in the context of available evidence...
  13. doi request reprint Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 4:51-62. 2011
    ..These studies sought to investigate the impact on mortality of coronary flow after passage of the wire through the culprit vessel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing mechanical reperfusion...
  14. ncbi request reprint High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, C rso Giovecca 203, 44100 Ferrara, Italy
    Cardiovasc Drugs Ther 18:225-30. 2004
    ..With current European list prices, the use of tirofiban instead of abciximab would save enough money to absorb the difference between SES and BMS...
  15. ncbi request reprint Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction
    Marco Valgimigli
    University of Ferrara, Ferrara, Italy
    J Am Coll Cardiol 43:2000-8. 2004
    ....
  16. doi request reprint Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
    Marco Valgimigli
    Cardiovascular Institute, Azienda Opedaliera Universitaria di Ferrara, Corso Giovecca 203, Ferrara 44100, Italy
    Eur Heart J 31:35-49. 2010
    ..To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab...
  17. ncbi request reprint The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial
    Marco Valgimigli
    Department of Cardiology, University of Ferrara, Ferrara, Italy
    J Am Coll Cardiol 44:14-9. 2004
    ..We sought to determine the safety and efficacy of high-dose bolus (HDB) tirofiban in high-risk patients undergoing percutaneous coronary intervention (PCI)...
  18. ncbi request reprint Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, S Anna Hospital, Corso Giovecca 203, Ferrara, Italy
    Circulation 119:3215-22. 2009
    ..Whether this reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents such as tirofiban, is unknown...
  19. ncbi request reprint Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
    JAMA 293:2109-17. 2005
    ..At current European list prices, the use of tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs bare-metal stents...
  20. ncbi request reprint [Markers of coronary damage. From diagnosis to prognosis]
    Marco Valgimigli
    Cattedra di Cardiologia, Universita, Ferrara
    Recenti Prog Med 96:566-72. 2005
    ..Several prospective epidemiological studies have documented an association between inflammatory markers and cardiovascular disease and their role in primary and secondary prevention and as predictor of mortality...
  21. ncbi request reprint The heart of coronary arteries
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, C rso Giovecca 203, 44100 Ferrara, Italy
    Eur Heart J 28:2063. 2007
  22. ncbi request reprint Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEG
    Marco Valgimigli
    Cardiology, University of Ferrara, Ferrara, Italy
    Am Heart J 154:39-45. 2007
    ..Similarly, whether tirofiban administered at high-bolus dose (HBD) followed by standard infusion is a valuable alternative to abciximab in the setting of ST-segment elevation myocardial infarction remains uncertain...
  23. ncbi request reprint Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    J Am Coll Cardiol 50:138-45. 2007
    ..Moreover, the distribution of clinical events in relation to thienopyridine discontinuation was thoroughly investigated...
  24. doi request reprint Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    JAMA 299:1788-99. 2008
    ..Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries...
  25. ncbi request reprint Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara Cardiovascular Institute, Arcispedale S Anna, C rso Giovecca 203, 44100 Ferrara, Italy
    Circulation 111:863-70. 2005
    ..Despite the recognition that several TNF family cytokines are elevated during myocardial infarction, their role in predicting subsequent prognosis in these setting remains poorly understood...
  26. ncbi request reprint CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure
    Marco Valgimigli
    University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Gussago, Italy
    Circulation 110:1209-12. 2004
    ..We investigated the pattern of CD34(+) cells and EPC mobilization during HF and their correlation with the severity and origin of the disease...
  27. doi request reprint Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy
    Cardiovasc Drugs Ther 22:313-20. 2008
    ....
  28. ncbi request reprint Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress
    Marco Valgimigli
    Department of Cardiology, University of Ferrara c o Arcispedale S Anna, Corso Giovecca 203, 44100 Ferrara, Italy
    Arch Biochem Biophys 420:255-61. 2003
    ..Thus, oxidative stress, irrespective of atherosclerotic disease stages, seems to represent a key phenomenon in vascular disease progression and possible prevention...
  29. doi request reprint Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Clin Appl Thromb Hemost 16:591-3. 2010
    ....